发布求助
文献互助 智能选刊 最新文献

Antidepressants - Preclinical, Clinical and Translational Aspects最新文献

筛选
英文 中文
Introductory Chapter: Antidepressants - Preclinical, Clinical and Translational Aspects 导论章:抗抑郁药-临床前，临床和转化方面
Antidepressants - Preclinical, Clinical and Translational Aspects Pub Date : 2019-11-20 DOI: 10.5772/intechopen.86476
B. Olivier
{"title":"Introductory Chapter: Antidepressants - Preclinical, Clinical and Translational Aspects","authors":"B. Olivier","doi":"10.5772/intechopen.86476","DOIUrl":"https://doi.org/10.5772/intechopen.86476","url":null,"abstract":"In 2011 two extensive studies were published about prevalence and associated disability, including the associated disease burden and financial costs, of brain diseases in Europe [1–3]. A shocking finding was that in a European population of more than 400 million people, approximately one-third suffered from a psychiatric or neurological disorder. In the psychiatric disorders, anxiety disorders had the highest 12-month prevalence (14%) and depression (7%), approximately 61.5 million people. The disability burden of psychiatric diseases including major depression is tremendous being defined in disability-adjusted life years (DALYs). In 2010, more than 26% of all cumulated disease burden in Europe was due to brain disorders; depression belongs to the top diseases with the highest DALYs. Major depression is a severe brain disorder associated with long-term disability and low quality of life. Suicide and suicidal attempts are highly associated with depression and have an enormous impact on relatives and society.","PeriodicalId":209157,"journal":{"name":"Antidepressants - Preclinical, Clinical and Translational Aspects","volume":"132 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134158430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistant Depression 抗抑郁
Antidepressants - Preclinical, Clinical and Translational Aspects Pub Date : 2019-11-20 DOI: 10.5772/intechopen.82568
Jose Alfonso Ontiveros
{"title":"Resistant Depression","authors":"Jose Alfonso Ontiveros","doi":"10.5772/intechopen.82568","DOIUrl":"https://doi.org/10.5772/intechopen.82568","url":null,"abstract":"The term resistant points out a clinical phenomenon in which there is a lack of response to one or more therapeutic interventions. Resistance to major depressive disorder treatment causes distress to patients and their relatives, and increases the number of hospital admissions, outpatient consultations, use of psychoactive drugs, and treatment costs. Despite its serious medical and psychosocial medical implications, the definition of treatment resistant depression continues to be ambiguous and controversial. The lack of an agreement on definition, as well as the research on the subject being difficult, limits the practical knowledge on the best treatment options for groups of treatment resistant depression (TRD) patients. We review the concept and definitions of treatment resistant depression as well as the medical literature on different treatment methods studied and comparative studies. Finally, some relevant neurobiological data are reviewed.","PeriodicalId":209157,"journal":{"name":"Antidepressants - Preclinical, Clinical and Translational Aspects","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129027350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The BDNF Loop 4 Dipeptide Mimetic Bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenediamide Is Active in a Depression Model in Mice after Acute Oral Administration 急性口服BDNF环4二肽模拟双(n -单琥珀酰-l -seryl- l-赖氨酸)六亚二胺对小鼠抑郁模型有活性
Antidepressants - Preclinical, Clinical and Translational Aspects Pub Date : 2019-10-23 DOI: 10.5772/intechopen.88244
P. Povarnina, Yulia N. Firsova, Anna V. Tallerova, Аrmen G. Mezhlumyan, Sergey V. Kruglov, Tatiana A. Antipova, Tatiana A. Gudasheva, Sergey B. Seredenin
{"title":"The BDNF Loop 4 Dipeptide Mimetic Bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenediamide Is Active in a Depression Model in Mice after Acute Oral Administration","authors":"P. Povarnina, Yulia N. Firsova, Anna V. Tallerova, Аrmen G. Mezhlumyan, Sergey V. Kruglov, Tatiana A. Antipova, Tatiana A. Gudasheva, Sergey B. Seredenin","doi":"10.5772/intechopen.88244","DOIUrl":"https://doi.org/10.5772/intechopen.88244","url":null,"abstract":"Low-molecular mimetic BDNF GSB-106, which is a substituted dimeric dipeptide, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, was designed and synthesized in the V. V. Zakusov Research Institute of Pharmacology. The dipeptide activates TrkB, PI3K/AKT, and MAPK/ ERK. GSB-106 is being developed as a potential antidepressant. Its antidepressant activity was detected in a number of rodent tests (0.1–1.0 mg/kg, ip; 0.5–5.0 mg/kg, po). In the present study, GSB-106 was shown to completely eliminate the manifestation of anhedonia in the sucrose preference test and to increase disturbed hippocampal synaptogenesis at acute oral administration (0.1 mg/kg) after 10-day social defeat stress in C57Bl/6 mice.","PeriodicalId":209157,"journal":{"name":"Antidepressants - Preclinical, Clinical and Translational Aspects","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116410518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Influences of Maternal Vulnerability and Antidepressant Treatment during Pregnancy on the Developing Offspring 妊娠期母亲脆弱性和抗抑郁治疗对后代发育的影响
Antidepressants - Preclinical, Clinical and Translational Aspects Pub Date : 2019-02-14 DOI: 10.5772/INTECHOPEN.83761
L. Staal, J. Olivier
{"title":"Influences of Maternal Vulnerability and Antidepressant Treatment during Pregnancy on the Developing Offspring","authors":"L. Staal, J. Olivier","doi":"10.5772/INTECHOPEN.83761","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.83761","url":null,"abstract":"Maternal vulnerability to adversity has long-term impact on the developing child. About 20% of the pregnant women suffer from affective disorders. Fetal exposure to maternal adversity may lead to detrimental consequences later in life. Maternal affective disorders are increasingly treated with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs). However, the long-term consequences for the offspring after exposure to this medication are unclear. The interplay between maternal adversity and SSRI treatment has been under investigation and here we discuss how maternal adversity and SSRIs are able to shape offspring development. Specifically, we will discuss animal models addressing behavioral outcomes to understand how the prenatal environment influences the health of the developing child across the life span.","PeriodicalId":209157,"journal":{"name":"Antidepressants - Preclinical, Clinical and Translational Aspects","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127342047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis 重新思考使用抗抑郁药治疗酒精使用障碍和抑郁症共病:神经发生的作用
Antidepressants - Preclinical, Clinical and Translational Aspects Pub Date : 2019-02-04 DOI: 10.5772/INTECHOPEN.83743
A. Ballesta, F. Alén, F. Fonseca, R. G. D. Heras, L. Orio
{"title":"Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis","authors":"A. Ballesta, F. Alén, F. Fonseca, R. G. D. Heras, L. Orio","doi":"10.5772/INTECHOPEN.83743","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.83743","url":null,"abstract":"Patients with alcohol use disorders (AUDs) are frequently treated with antidepressant drugs (ADs), but clinical evidence of their efficacy is contradictory. Considering that ADs are thought to produce their therapeutic effects partially by increasing hippocampal plasticity and neurogenesis (HN), and that both AUDs and depression share a potential for the disruption of these neuroplastic processes, one could reason-ably wonder whether the poor efficacy of AD treatment could be explained by the inability of these drugs to exert their proper action in patients suffering from AUD or depression. In order to further clarify this question, this chapter aims to examine available data regarding the effect of ADs on behavioral and HN alterations related to alcohol abstinence, as a key period in which the treatment would be implemented and in which their potential effects on alcohol-related problems remain under controversy.","PeriodicalId":209157,"journal":{"name":"Antidepressants - Preclinical, Clinical and Translational Aspects","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131423080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens 食欲素2受体拮抗剂从前额皮质回路到啮齿动物行为筛选
Antidepressants - Preclinical, Clinical and Translational Aspects Pub Date : 2019-02-01 DOI: 10.5772/INTECHOPEN.82544
G. Marek, S. Chaney, M. Benvenga
{"title":"Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens","authors":"G. Marek, S. Chaney, M. Benvenga","doi":"10.5772/INTECHOPEN.82544","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.82544","url":null,"abstract":"Orexin is a neuropeptide contained in neurons from several hypothalamic nuclei that project throughout the forebrain analogously to monoamines synthesized by brainstem nuclei. Orexin, like 5-hydroxytryptamine (5-HT), norepinephrine (NE), dopamine (DA), histamine and acetylcholine (ACh) exerts prominent effects on the sleep-wake cycle of all mammals. Activation of the orexin 2 receptor appears to induce spontaneous excitatory synaptic currents (EPSCs) on layer V pyramidal neurons due to release of glutamate from thalamocortical terminals similar to activation of 5-HT 2A and α 1 -adrenergic receptors. Layer V pyramidal cells are the major descending output cell in the prefrontal cortex with projections to the thalamus, striatum, amygdala, brainstem and spinal cord. In keeping with salient modulation of prefrontal cortical physiology, orexin 2 receptor antagonists exert similar effects to 5-HT 2A receptor antagonists in suppressing hallucinogen (e.g., DOI)-induced head twitches and producing antidepressant-like effects on the differential-reinforcement-of-low-rate 72-s (DRL 72-s) schedule of reinforcement. Currently, there is both negative and some preliminary positive evidence that blocking orexin 2 receptors may result in antidepressant efficacy in patients with major depressive disorder. Overall, the treatment of mood disorders is an additional potential indica-tion for orexin receptor antagonists beyond simply improving sleep.","PeriodicalId":209157,"journal":{"name":"Antidepressants - Preclinical, Clinical and Translational Aspects","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131059502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信